Weekly Endocrinology Research Analysis
This week’s endocrinology literature converged on durable metabolic interventions and mechanistic targets that can change clinical practice: (1) oral GLP-1 therapy (orforglipron) and continued tirzepatide demonstrate that maintenance pharmacotherapy is necessary to preserve injectable-induced weight loss; (2) mechanistic studies nominate actionable targets — VE-cadherin Y685 phosphorylation in diabetic retinopathy and IL-11/IL-11Ra in adipose thermogenesis — with translational potential; (3) mul
Summary
This week’s endocrinology literature converged on durable metabolic interventions and mechanistic targets that can change clinical practice: (1) oral GLP-1 therapy (orforglipron) and continued tirzepatide demonstrate that maintenance pharmacotherapy is necessary to preserve injectable-induced weight loss; (2) mechanistic studies nominate actionable targets — VE-cadherin Y685 phosphorylation in diabetic retinopathy and IL-11/IL-11Ra in adipose thermogenesis — with translational potential; (3) multi-omics microbiome–host work identifies gut-derived ammonia as an immune driver of MASH and a treatable axis (DT-109). These findings span late-phase RCTs to cross-species mechanistic validation and should influence therapy selection, perioperative/diagnostic strategies, and biomarker-driven trials.
Selected Articles
1. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
In two cohorts of patients who reached a weight-loss plateau after tirzepatide or semaglutide, switching to once-daily oral orforglipron preserved substantially more prior weight loss over 52 weeks than placebo (maintained ~75–79% vs 37–49% with placebo). Safety was consistent with the GLP-1 class, predominantly mild-to-moderate gastrointestinal events. The trial addresses the practical need for scalable, oral maintenance options after injectable-induced weight reduction.
Impact: Provides randomized, double-blind, phase 3b evidence that an oral GLP-1 receptor agonist can maintain injectable-induced weight loss, offering a scalable adherence-friendly maintenance strategy.
Clinical Implications: Clinicians can consider transitioning patients who plateau on tirzepatide/semaglutide to oral orforglipron to preserve weight loss when continued injectable therapy is impractical; counsel about GI side effects and note lack of a head-to-head continuation arm.
Key Findings
- Orforglipron maintained ~74.7% of prior weight loss after tirzepatide vs 49.2% with placebo at 52 weeks (cohort 1).
- Orforglipron maintained ~79.3% of prior weight loss after semaglutide vs 37.6% with placebo at 52 weeks (cohort 2).
- Adverse events were mainly mild-to-moderate GI symptoms; no new safety signals beyond GLP-1 class expectations.
2. Disrupting VE-cadherin Y685 phosphorylation inhibits development of experimental diabetic and prediabetic retinopathy.
This mechanistic study shows VE-cadherin Y685 phosphorylation is induced by high glucose/NDPKB deficiency and drives junctional internalization, O-GlcNAc–mediated Ang2 upregulation, endothelial barrier breakdown, and pericyte detachment. A Y685F knock-in protected mice from retinal hyperpermeability and neurovascular dysfunction, nominating VE-cadherin Y685 and downstream O-GlcNAc/Ang2 signaling as actionable targets to prevent early diabetic retinal injury.
Impact: Identifies an upstream, targetable endothelial phosphorylation event that precedes pericyte loss and vascular leakage in diabetic retinopathy and provides mechanistic support for developing pharmacologic inhibitors or modulators of O-GlcNAc/Ang2 signaling.
Clinical Implications: Translational development of small molecules or biologics that prevent VE-cadherin Y685 phosphorylation or modulate O-GlcNAc/Ang2 may preserve retinal barrier integrity in early diabetes/prediabetes; human biomarker studies of junctional integrity are a next step.
Key Findings
- High glucose and NDPKB deficiency induce VE-cadherin Y685 phosphorylation leading to junctional internalization and Ang2 upregulation.
- VE-cadherin Y685F knock-in mice were protected from diabetes- and prediabetes-induced vascular hyperpermeability and neurovascular dysfunction.
- O-GlcNAc modification mediates Y685-dependent Ang2 induction; modulating this axis restored neurovascular and mitochondrial pathways.
3. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
After a 60-week induction with tirzepatide at maximum tolerated dose, continuing tirzepatide for a further 52-week double-blind maintenance period sustained weight loss and related health benefits compared with dose reduction to 5 mg or stopping (placebo). The trial supports ongoing therapy for long-term obesity management and shows dose-reduction retains partial benefit if continuation at MTD is not feasible.
Impact: Definitive multicentre randomized evidence that continued tirzepatide is required to sustain clinically meaningful weight loss and benefits, directly informing long-term dosing, tapering, and patient counseling in obesity care.
Clinical Implications: For chronic obesity management, clinicians should plan for long-term tirzepatide therapy at tolerated doses when feasible; consider 5 mg dose reduction only when required and counsel patients about likely partial regain if therapy is stopped.
Key Findings
- Continuing tirzepatide at MTD sustained weight loss and health-related benefits over 52 weeks compared with dose reduction or stopping.
- Dose reduction to 5 mg preserved some benefit and may be an alternative when continuation at MTD is not feasible.
- High trial completion (91%) and clinically relevant outcomes support practical guidance for long-term obesity pharmacotherapy.